BG101175A - Тройна анти-нiv комбинация - Google Patents

Тройна анти-нiv комбинация

Info

Publication number
BG101175A
BG101175A BG101175A BG10117597A BG101175A BG 101175 A BG101175 A BG 101175A BG 101175 A BG101175 A BG 101175A BG 10117597 A BG10117597 A BG 10117597A BG 101175 A BG101175 A BG 101175A
Authority
BG
Bulgaria
Prior art keywords
combination
trium
liv
aids
treatment
Prior art date
Application number
BG101175A
Other languages
English (en)
Inventor
Paulus STOFFELS
Koenraad Andries
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of BG101175A publication Critical patent/BG101175A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Изобретението се отнася до терапевтична комбинация, съдържаща зидовудин, ламивудин и ловирид, за лечение на инфекциозни заболявания, причинени от вирусана човешката имунна недостатъчност (HIV), по-специално на СПИН (AIDS) и на свързания със СПИН комплекс (ARС).
BG101175A 1994-07-01 1997-01-27 Тройна анти-нiv комбинация BG101175A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94201897 1994-07-01
PCT/EP1995/002462 WO1996001110A2 (en) 1994-07-01 1995-06-23 Anti-hiv triple combination

Publications (1)

Publication Number Publication Date
BG101175A true BG101175A (bg) 1997-08-29

Family

ID=8217000

Family Applications (1)

Application Number Title Priority Date Filing Date
BG101175A BG101175A (bg) 1994-07-01 1997-01-27 Тройна анти-нiv комбинация

Country Status (25)

Country Link
EP (1) EP0768881B1 (bg)
JP (1) JP2945481B2 (bg)
KR (1) KR100218495B1 (bg)
CN (1) CN1091599C (bg)
AP (1) AP9600896A0 (bg)
AT (1) ATE218867T1 (bg)
AU (1) AU693911B2 (bg)
BG (1) BG101175A (bg)
BR (1) BR9508201A (bg)
CA (1) CA2193489A1 (bg)
CZ (1) CZ375596A3 (bg)
DE (1) DE69527066T2 (bg)
EE (1) EE9600180A (bg)
FI (1) FI965292A7 (bg)
HU (1) HUT77720A (bg)
IL (1) IL114415A0 (bg)
MX (1) MX9700044A (bg)
MY (1) MY130597A (bg)
NO (1) NO965556D0 (bg)
OA (1) OA10341A (bg)
PL (1) PL317891A1 (bg)
SK (1) SK168196A3 (bg)
TW (1) TW401303B (bg)
WO (1) WO1996001110A2 (bg)
ZA (1) ZA955471B (bg)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0942747A1 (en) * 1996-08-26 1999-09-22 Chiron Corporation Postinfection human immunodeficiency virus (hiv) vaccination therapy
EP0872233A1 (en) * 1997-04-14 1998-10-21 Janssen Pharmaceutica N.V. Antiretroviral compositions with improved bioavailability
CA2384188C (en) 1999-09-24 2008-06-17 Janssen Pharmaceutica N.V. Antiviral compositions
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US9044509B2 (en) 2006-02-03 2015-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibition of HIV infection through chemoprophylaxis
CL2008000746A1 (es) 2007-03-14 2008-09-22 Tibotec Pharm Ltd Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida.
US8481554B2 (en) 2009-05-27 2013-07-09 Hetero Research Foundation Solid oral dosage forms of lamivudine
WO2018119371A1 (en) * 2016-12-23 2018-06-28 Temple University - Of The Commonwealth System Of Higher Education Anti-flaviviridae activity of anti-retroviral non-nucleoside (nnrtis) and nucleoside reverse transcriptase inhibitors (nnrtis)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992020344A1 (en) * 1991-05-16 1992-11-26 Glaxo Group Limited Antiviral combinations containing nucleoside analogs

Also Published As

Publication number Publication date
ATE218867T1 (de) 2002-06-15
EP0768881B1 (en) 2002-06-12
EE9600180A (et) 1997-06-16
IL114415A0 (en) 1995-10-31
ZA955471B (en) 1996-12-30
WO1996001110A2 (en) 1996-01-18
CN1151697A (zh) 1997-06-11
KR100218495B1 (en) 1999-09-01
DE69527066T2 (de) 2003-02-13
CA2193489A1 (en) 1996-01-18
EP0768881A2 (en) 1997-04-23
NO965556L (no) 1996-12-23
TW401303B (en) 2000-08-11
AP9600896A0 (en) 1997-01-31
BR9508201A (pt) 1997-11-11
MY130597A (en) 2007-07-31
FI965292A0 (fi) 1996-12-31
MX9700044A (es) 1997-04-30
OA10341A (en) 1997-10-07
DE69527066D1 (de) 2002-07-18
JP2945481B2 (ja) 1999-09-06
CN1091599C (zh) 2002-10-02
FI965292L (fi) 1996-12-31
WO1996001110A3 (en) 1996-02-22
HU9603627D0 (en) 1997-02-28
FI965292A7 (fi) 1996-12-31
HUT77720A (hu) 1998-07-28
AU693911B2 (en) 1998-07-09
CZ375596A3 (en) 1997-04-16
NO965556D0 (no) 1996-12-23
PL317891A1 (en) 1997-04-28
JPH09507858A (ja) 1997-08-12
SK168196A3 (en) 1997-05-07
AU2924895A (en) 1996-01-25

Similar Documents

Publication Publication Date Title
BR9710355A (pt) Composição útil para o tratamento de infecções virais em um mamìfero, processo para tratar uma infecção viral em um mamìfero, e, produto medicinal.
WO2001010456A3 (en) Peptides that block viral infectivity and methods of use thereof
NO20005839D0 (no) Preparater for behandling av HIV og andre virale infeksjoner
ZA913910B (en) Use of baclofen for obtaining medicaments for the treatment of angina pectoris
EP0853662A4 (en) NEW REPLICABLE HUMAN IMMUNE WEAKNESS VIRUS TYPE II (HIV-2) PROVIRAL CLONE HIV-2KR
BG101175A (bg) Тройна анти-нiv комбинация
PL353033A1 (en) Anti-hiv 1 vaccine comprising the entire or part of the tat hiv-1 protein
AU4088697A (en) Postinfection human immunodeficiency virus (hiv) vaccination therapy
AU2002219881A1 (en) Methods and compositions for the treatment of human immunodeficiency virus infection
AU5848794A (en) Multiple-gene mutants of human immunodeficiency virus (hiv) for vaccine use
HUP0000344A2 (hu) Lamivudint és zidovudint tartalmazó gyógyszerkészítmények
CA2195125A1 (en) Difluorostatone antiviral agents
JP2002508338A5 (bg)
AU2880595A (en) Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
AP9400647A0 (en) Medicaments for use in treatment of HIV or cancer patients.
AU4111600A (en) The use of gssg reductase for the therapy and prophylaxis of hiv infected patients
EP0316592A3 (en) 3'-fluoro-2',3'-dideoxyuridine, and its therapeutic application
UA41338C2 (uk) Спосіб інгібування ретровірусної інфекції, яка викликана вірусом імунодефіциту людини (віл), спосіб інгібування вірусу імунодефіциту людини (віл)
ZA945416B (en) Method of inhibiting the production of infectious human immunodeficiency viruses (HIV) in HIV seropositive humans.
AU3593095A (en) Method of treatment of human immunodeficiency virus (hiv) infection
AP9801368A0 (en) Benzamide treatment of mentia associated with HIV AIDS VIRUS (HIV-1) infection
AP2003002847A0 (en) Immunomodulator for the management of human immunodeficiency virus (HIV) disease / infection.
AU1189899A (en) Inhibition of human immunodeficiency virus (hiv-1) replication
BR0109345A (pt) Compostos com atividade anti-hiv
HU9602158D0 (en) Macrocyclic difluorostatone derivatives useful as antiviral agents